Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Poxvirus Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Poxvirus Infections - Pipeline Review, H2 2014', provides an overview of the Poxvirus Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Poxvirus Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Poxvirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Poxvirus Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Poxvirus Infections Overview 6 Therapeutics Development 7 Pipeline Products for Poxvirus Infections - Overview 7 Pipeline Products for Poxvirus Infections - Comparative Analysis 8 Poxvirus Infections - Therapeutics under Development by Companies 9 Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes 10 Poxvirus Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Unknown Stage Products 13 Poxvirus Infections - Products under Development by Companies 14 Poxvirus Infections - Products under Investigation by Universities/Institutes 15 Poxvirus Infections - Companies Involved in Therapeutics Development 16 BioApex, s.r.o. 16 SIGA Technologies, Inc. 17 Takeda Pharmaceutical Company Limited 18 Poxvirus Infections - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 4-ThioIDU - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Antibody for Poxvirus Infections - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 BA-368 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 modified vaccinia ankara vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecule to Inhibit DNA Synthesis for Viral Infections - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules to Inhibit Viral DNA Polymerase for Herpes and Poxvirus Infections - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 tecovirimat - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Poxvirus Infections - Recent Pipeline Updates 38 Poxvirus Infections - Dormant Projects 40 Poxvirus Infections - Product Development Milestones 41 Featured News & Press Releases 41 Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 43 Disclaimer 43
List of Tables Number of Products under Development for Poxvirus Infections, H2 2014 7 Number of Products under Development for Poxvirus Infections - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Clinical Stage Development, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Comparative Analysis by Unknown Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Poxvirus Infections - Pipeline by BioApex, s.r.o., H2 2014 16 Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H2 2014 17 Poxvirus Infections - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Poxvirus Infections Therapeutics - Recent Pipeline Updates, H2 2014 38 Poxvirus Infections - Dormant Projects, H2 2014 40
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
